267 related articles for article (PubMed ID: 27856256)
21. Calcineurin/NFAT signaling pathway mediates titanium particle‑induced inflammation and osteoclast formation by inhibiting RANKL and M‑CSF in vitro.
Zhang Y; Jiang P; Li W; Liu X; Lu Y; Huang Z; Song K
Mol Med Rep; 2017 Dec; 16(6):8223-8230. PubMed ID: 28990090
[TBL] [Abstract][Full Text] [Related]
22. Orai1-mediated calcium entry plays a critical role in osteoclast differentiation and function by regulating activation of the transcription factor NFATc1.
Hwang SY; Putney JW
FASEB J; 2012 Apr; 26(4):1484-92. PubMed ID: 22198385
[TBL] [Abstract][Full Text] [Related]
23. Decoy receptor 3 suppresses RANKL-induced osteoclastogenesis via down-regulating NFATc1 and enhancing cell apoptosis.
Cheng CP; Sheu MJ; Sytwu HK; Chang DM
Rheumatology (Oxford); 2013 Apr; 52(4):609-22. PubMed ID: 23221330
[TBL] [Abstract][Full Text] [Related]
24. Interleukin 26 suppresses receptor activator of nuclear factor κB ligand induced osteoclastogenesis via down-regulation of nuclear factor of activated T-cells, cytoplasmic 1 and nuclear factor κB activity.
Peng YJ; Wang CY; Lin YH; Lin GJ; Huang SH; Shyu JF; Sytwu HK; Cheng CP
Rheumatology (Oxford); 2016 Nov; 55(11):2074-2083. PubMed ID: 27550297
[TBL] [Abstract][Full Text] [Related]
25. Iguratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-κB and MAPK pathways.
Gan K; Yang L; Xu L; Feng X; Zhang Q; Wang F; Tan W; Zhang M
Int Immunopharmacol; 2016 Jun; 35():294-300. PubMed ID: 27085680
[TBL] [Abstract][Full Text] [Related]
26. Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB.
Kang MR; Jo SA; Yoon YD; Park KH; Oh SJ; Yun J; Lee CW; Nam KH; Kim Y; Han SB; Yu J; Rho J; Kang JS
Mar Drugs; 2014 Nov; 12(11):5643-56. PubMed ID: 25421321
[TBL] [Abstract][Full Text] [Related]
27. Lumichrome inhibits osteoclastogenesis and bone resorption through suppressing RANKL-induced NFAT activation and calcium signaling.
Liu C; Cao Z; Zhang W; Tickner J; Qiu H; Wang C; Chen K; Wang Z; Tan R; Dong S; Xu J
J Cell Physiol; 2018 Nov; 233(11):8971-8983. PubMed ID: 29904917
[TBL] [Abstract][Full Text] [Related]
28. Helvolic acid attenuates osteoclast formation and function via suppressing RANKL-induced NFATc1 activation.
Chen K; Yuan Y; Wang Z; Song D; Zhao J; Cao Z; Chen J; Guo Q; Chen L; Tickner J; Xu J
J Cell Physiol; 2019 May; 234(5):6477-6488. PubMed ID: 30341897
[TBL] [Abstract][Full Text] [Related]
29. RANKL-induced TRPV2 expression regulates osteoclastogenesis via calcium oscillations.
Kajiya H; Okamoto F; Nemoto T; Kimachi K; Toh-Goto K; Nakayana S; Okabe K
Cell Calcium; 2010 Nov; 48(5):260-9. PubMed ID: 20980052
[TBL] [Abstract][Full Text] [Related]
30. Sophorae Flos extract inhibits RANKL-induced osteoclast differentiation by suppressing the NF-κB/NFATc1 pathway in mouse bone marrow cells.
Kim JM; Lee JH; Lee GS; Noh EM; Song HK; Gu DR; Kim SC; Lee SH; Kwon KB; Lee YR
BMC Complement Altern Med; 2017 Mar; 17(1):164. PubMed ID: 28335757
[TBL] [Abstract][Full Text] [Related]
31. Aconine inhibits RANKL-induced osteoclast differentiation in RAW264.7 cells by suppressing NF-κB and NFATc1 activation and DC-STAMP expression.
Zeng XZ; He LG; Wang S; Wang K; Zhang YY; Tao L; Li XJ; Liu SW
Acta Pharmacol Sin; 2016 Feb; 37(2):255-63. PubMed ID: 26592521
[TBL] [Abstract][Full Text] [Related]
32. Hispidulin attenuates bone resorption and osteoclastogenesis via the RANKL-induced NF-κB and NFATc1 pathways.
Nepal M; Choi HJ; Choi BY; Yang MS; Chae JI; Li L; Soh Y
Eur J Pharmacol; 2013 Sep; 715(1-3):96-104. PubMed ID: 23791609
[TBL] [Abstract][Full Text] [Related]
33. Myricetin suppresses LPS-induced MMP expression in human gingival fibroblasts and inhibits osteoclastogenesis by downregulating NFATc1 in RANKL-induced RAW 264.7 cells.
Ko SY
Arch Oral Biol; 2012 Dec; 57(12):1623-32. PubMed ID: 22795564
[TBL] [Abstract][Full Text] [Related]
34. Artesunate attenuates LPS-induced osteoclastogenesis by suppressing TLR4/TRAF6 and PLCγ1-Ca
Zeng XZ; Zhang YY; Yang Q; Wang S; Zou BH; Tan YH; Zou M; Liu SW; Li XJ
Acta Pharmacol Sin; 2020 Feb; 41(2):229-236. PubMed ID: 31431733
[TBL] [Abstract][Full Text] [Related]
35. The calcineurin/nuclear factor of activated T cells signaling pathway regulates osteoclastogenesis in RAW264.7 cells.
Hirotani H; Tuohy NA; Woo JT; Stern PH; Clipstone NA
J Biol Chem; 2004 Apr; 279(14):13984-92. PubMed ID: 14722106
[TBL] [Abstract][Full Text] [Related]
36. WSS25, a sulfated polysaccharide, inhibits RANKL-induced mouse osteoclast formation by blocking SMAD/ID1 signaling.
Chen C; Qin Y; Fang JP; Ni XY; Yao J; Wang HY; Ding K
Acta Pharmacol Sin; 2015 Sep; 36(9):1053-64. PubMed ID: 26299951
[TBL] [Abstract][Full Text] [Related]
37. Flunarizine inhibits osteoclastogenesis by regulating calcium signaling and promotes osteogenesis.
Kim HJ; Lee J; Lee GR; Kim N; Lee HI; Kwon M; Kim NY; Park JH; Kang YH; Song HJ; Kim T; Shin DM; Jeong W
J Cell Physiol; 2021 Dec; 236(12):8239-8252. PubMed ID: 34192358
[TBL] [Abstract][Full Text] [Related]
38. Cot kinase promotes Ca2+ oscillation/calcineurin-independent osteoclastogenesis by stabilizing NFATc1 protein.
Kuroda Y; Hisatsune C; Mizutani A; Ogawa N; Matsuo K; Mikoshiba K
Mol Cell Biol; 2012 Jul; 32(14):2954-63. PubMed ID: 22615493
[TBL] [Abstract][Full Text] [Related]
39. Asperpyrone A attenuates RANKL-induced osteoclast formation through inhibiting NFATc1, Ca
Chen X; Wang C; Qiu H; Yuan Y; Chen K; Cao Z; Xiang Tan R; Tickner J; Xu J; Zou J
J Cell Mol Med; 2019 Dec; 23(12):8269-8279. PubMed ID: 31612613
[TBL] [Abstract][Full Text] [Related]
40. Fluid Shear Stress Suppresses Osteoclast Differentiation in RAW264.7 Cells through Extracellular Signal-Regulated Kinase 5 (ERK5) Signaling Pathway.
Ma C; Geng B; Zhang X; Li R; Yang X; Xia Y
Med Sci Monit; 2020 Jan; 26():e918370. PubMed ID: 31914120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
